Truist Securities Reiterates Hold on Corcept Therapeutics, Maintains $29 Price Target
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Joon Lee has reiterated a 'Hold' rating on Corcept Therapeutics (NASDAQ:CORT) and maintained a price target of $29.
October 02, 2023 | 4:27 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Corcept Therapeutics' stock rating has been reiterated as 'Hold' by Truist Securities with a maintained price target of $29.
The reiteration of the 'Hold' rating and maintained price target by Truist Securities indicates that the analyst believes the stock is fairly valued at its current price. This could mean that the stock price may not see significant movement in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100